Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 13th April 2023
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Participants sought for canine epilepsy study
The study will evaluate the safety and efficacy of a new epilepsy medication.
Researchers are seeking epileptic dogs aged 2 years and over.

Owners of epileptic dogs are being sought for a clinical trial of a new epilepsy treatment. The study is being undertaken by researchers at the University of Glasgow in collaboration with the Royal College of Surgeons in Ireland and funded by American-based charity, Cure Epilepsy.

The researchers hope to acquire new knowledge to help many dogs, and maybe even humans with epilepsy in the future.

The epilepsy medication being evaluated for the study has never been used in dogs or humans before. Researchers will test how safe and effective it is for dogs with canine idiopathic epilepsy who have not responded to conventional anti-seizure medications.

Canine epilepsy affects over 50,000 dogs in the UK, and approximately one third of those do not respond to conventional anti-seizure medications.

To be eligible for the study a dog needs to fit the following criteria:
  • Aged 2 years or over
  • Weighs more than 5 kilograms
  • Has had a diagnosis of idiopathic epilepsy with a normal MRI scan and CSF
  • Has more than four seizures per month despite having tried at least two anti-seizure medications
  • Is deemed otherwise healthy

Owners will be required to attend a number of appointments with their dog at the study site based at the University of Glasgow, and will also be asked to keep a record of their dog’s seizures.

Dogs will be randomly put into one of two study groups; one group will receive the study medication, the other will receive a placebo. Neither the dog owner or study veterinarian will know which group is receiving the study medication or the placebo.

Rodrigo Gutierrez Quintana, senior clinician in veterinary neurology at the University of Glasgow said: “In this clinical trial we will be evaluating the safety and efficacy of a completely new treatment option for epilepsy in dogs. We are very excited to use an RNA-based therapy that targets microRNA-134. Currently, one third of epileptic dogs do not respond to anti-seizure medications, and this new therapy could represent an option for these cases.”

If there is evidence that the study medication is safe and effective, it will be offered to the dogs that received the placebo.

More information about the study can be found on the University of Glasgow’s website.

 

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.